.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Find suppliers and generic API sources

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cipla
Accenture
Harvard Business School
Medtronic
McKinsey
Chubb
Express Scripts
Cerilliant
Moodys

Generated: July 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020236

« Back to Dashboard
NDA 020236 describes SEREVENT, which is a drug marketed by Glaxosmithkline and is included in two NDAs. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the SEREVENT profile page.

The generic ingredient in SEREVENT is salmeterol xinafoate. There are eighteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the salmeterol xinafoate profile page.

Summary for NDA: 020236

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:AEROSOL, METERED;INHALATIONStrengthEQ 0.021MG BASE/INH
Approval Date:Feb 4, 1994TE:RLD:No

Expired Orange Book Patents for NDA: 020236

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
SEREVENT
salmeterol xinafoate
AEROSOL, METERED;INHALATION020236-001Feb 4, 1994► Subscribe► Subscribe
Glaxosmithkline
SEREVENT
salmeterol xinafoate
AEROSOL, METERED;INHALATION020236-001Feb 4, 1994► Subscribe► Subscribe
Glaxosmithkline
SEREVENT
salmeterol xinafoate
AEROSOL, METERED;INHALATION020236-001Feb 4, 1994► Subscribe► Subscribe
Glaxosmithkline
SEREVENT
salmeterol xinafoate
AEROSOL, METERED;INHALATION020236-001Feb 4, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Merck
Cipla
Accenture
Daiichi Sankyo
Citi
Fuji
Deloitte
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot